Please select the option that best describes you:
Would you consider first-line cabozantinib in patients with intermediate- or poor-risk mRCC?
The CABOSUN trial showed a benefit in PFS and ORR, with unchanged OS, over sunitinib.
Answer from: Medical Oncologist at Academic Institution
Although the results from the phase II CABOSUN trial were intriquing, I would not consider cabozantinib as first line therapy for patients with intermediate or poor-risk mRCC. There were a number of concerning results. Firstly, the extremely low PFS of ~5months in the sunitinib-treated pat...
Sign in or Register to read more